News

Nov 17,2022

Apexigen Announces Positive Interim Results from Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Doxorubicin in Patients with Liposarcoma

Nov 11,2022

Subtle Medical Joins Imaging AI in Practice Demonstration at RSNA 2022

Nov 10,2022

Lipidio Pharmaceuticals Announces Close of Series A Extension Financing, Bringing Total Round to Over $20M

Nov 08,2022

Profusa, Inc., a Digital Health Company, Pioneering the Next Generation of Personalized Medicine, to Become a Publicly Traded Company Via Merger with NorthView Acquisition Corp

Nov 08,2022

OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with pembrolizumab at SITC 2022

Nov 01,2022

Avirmax CMC Inc. Received License for cGMP Gene Therapy Vector Production by the California Department of Public Health

Oct 26,2022

Quadriga BioSciences Announces Completion of Enrollment in Phase 1 Study of QBS72S for Solid Tumors

Oct 08,2022

Avirmax Inc. Announces Issuance of U.S. Patent Covering Catalysis Deactivated Angiotensin-Converting Enzyme 2 (ACE2) Variants for Treatment of Beta Group SARS-COV Viral Infection

End of content

No more pages to load